20.109(F12) Pre-Proposal: Viral mitigation of insulin resistance
From OpenWetWare
(→Your idea) |
(→Your idea) |
||
| Line 16: | Line 16: | ||
*Why is this field important | *Why is this field important | ||
==Your idea== | ==Your idea== | ||
| - | Personal health is of great concern to today's society, especially in relation to weight loss. The rate of Type 2 diabetes in the human population has increased alongside the rate of obesity; it has been clear for some time that excessive | + | Personal health is of great concern to today's society, especially in relation to weight loss. The rate of Type 2 diabetes in the human population has increased alongside the rate of obesity; it has been clear for some time that excessive weight gain can lead to insulin resistance which is a direct cause of Type 2 diabetes. Presently, the accepted method of prevention and alleviation of obesity and its related ailments is diet and exercise. Drug based weight-loss methods have not been exhaustively explored; of the drugs that have been explored, very few act directly on the adipose cells and the products they secrete. Because mouse adipocytes have been implicated in accelerating the development of insulin resistance through the production of resistin and because increased levels of resisitin can be found in humans that are insulin resistant, the formation of a new therapy that targets resistin could be beneficial in preventing and/or reducing the degree of insulin resistance in any given individual. |
==A sketch== | ==A sketch== | ||
[[Image:Preproposal_Diagram.jpg]] | [[Image:Preproposal_Diagram.jpg]] | ||
Revision as of 06:17, 29 November 2012
Contents |
Investigators
- Stanley Gill
- Amy Liu
- T/R 20.109 Lab
- Team Yellow
Title of Proposed Project
Antibody-based Regulation of Resistin Levels through a Synthetic Circuit Injected via Vector Immunoprophylaxis
Project Summary
One of the hallmark characteristics of obesity and Type 2 diabetes is insulin resistance. Resistin, a peptide produced by endocrine adipocytes in mice, has been implicated in increasing the likelihood of insulin resistance and is present in high levels in the blood of obese patients. Here, we explore that the introduction of a regulated synthetic system that produces antibodies against resistin may stave off insulin resistance, alleviating and preventing the development of Type 2 diabetes.
Introduction
ONE PARAGRAPH and at least TWO REFERENCES
- What is known about this field
- Why is this field important
Your idea
Personal health is of great concern to today's society, especially in relation to weight loss. The rate of Type 2 diabetes in the human population has increased alongside the rate of obesity; it has been clear for some time that excessive weight gain can lead to insulin resistance which is a direct cause of Type 2 diabetes. Presently, the accepted method of prevention and alleviation of obesity and its related ailments is diet and exercise. Drug based weight-loss methods have not been exhaustively explored; of the drugs that have been explored, very few act directly on the adipose cells and the products they secrete. Because mouse adipocytes have been implicated in accelerating the development of insulin resistance through the production of resistin and because increased levels of resisitin can be found in humans that are insulin resistant, the formation of a new therapy that targets resistin could be beneficial in preventing and/or reducing the degree of insulin resistance in any given individual.
A sketch
